Miraculins Taps Inverness to Commercialize Preeclampsia Biomarkers

Inverness, through its Biosite division, will develop and evaluate tests using Miraculins' panel of 35 biomarkers for placenta development and preeclampsia.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.